[S02DA03, antipyrine, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Antipyrine.]
[J01GA01, streptomycin, Metoclopramide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The metabolism of Succinylcholine can be decreased when combined with Metoclopramide.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01CG01, sulbactam, Metoclopramide may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Metoclopramide.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Metoclopramide.]
[J01EB04, sulfapyridine, The risk or severity of methemoglobinemia can be increased when Sulfapyridine is combined with Metoclopramide.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of sedation can be increased when Metoclopramide is combined with Sulthiame.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Metoclopramide.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Metoclopramide.]
[N05CD07, temazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Temazepam.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metoclopramide.]
[B01AE07, dabigatran etexilate, Metoclopramide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of sedation can be increased when Metoclopramide is combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of sedation can be increased when Metoclopramide is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of sedation can be increased when Metoclopramide is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Metoclopramide.]
[P02CA02, thiabendazole, The metabolism of Metoclopramide can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiethylperazine.]
[N05CA19, thiopental, The risk or severity of sedation can be increased when Metoclopramide is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Metoclopramide.]
[G04BE06, moxisylyte, Metoclopramide may increase the neuromuscular blocking activities of Moxisylyte.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Metoclopramide.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Metoclopramide.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Metoclopramide can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Metoclopramide.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01AA12, tobramycin, Metoclopramide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of sedation can be increased when Metoclopramide is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Metoclopramide.]
[S01BA05, triamcinolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mepenzolate.]
[A16AX12, trientine, Metoclopramide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.]
[D07AC02, fluclorolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Metoclopramide.]
[R03BA07, mometasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.]
[C01EB15, trimetazidine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.]
[N03AC02, trimethadione, The risk or severity of sedation can be increased when Metoclopramide is combined with Trimethadione.]
[C02BA01, trimethaphan, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Metoclopramide.]
[N06AA06, trimipramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Trimipramine.]
[R06AC04, tripelennamine, The metabolism of Metoclopramide can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Triprolidine.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Metoclopramide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of sedation can be increased when Metoclopramide is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of sedation can be increased when Metoclopramide is combined with Tryptophan.]
[M03AA02, tubocurarine, The risk or severity of sedation can be increased when Metoclopramide is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Metoclopramide.]
[L01FX04, ipilimumab, Metoclopramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Metoclopramide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Metoclopramide can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Metoclopramide can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Metoclopramide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Metoclopramide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rilpivirine.]
[S01AA28, vancomycin, Metoclopramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of sedation can be increased when Metoclopramide is combined with Ezogabine.]
[B01AF01, rivaroxaban, Metoclopramide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Metoclopramide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of sedation can be increased when Metoclopramide is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Metoclopramide can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Metoclopramide.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[B01AA03, warfarin, Metoclopramide may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Metoclopramide can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Metoclopramide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Metoclopramide can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of sedation can be increased when Metoclopramide is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Metoclopramide can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Metoclopramide.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[B06AC02, icatibant, Metoclopramide may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Metoclopramide can be decreased when combined with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metoclopramide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Metoclopramide may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Metoclopramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tolterodine.]
[J01DH04, doripenem, Metoclopramide may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Metoclopramide may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Metoclopramide can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Metoclopramide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of sedation can be increased when Metoclopramide is combined with Atracurium.]
[S01FA01, atropine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Metoclopramide.]
[H02AB11, prednylidene, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Metoclopramide may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Metoclopramide can be decreased when combined with Azathioprine.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Metoclopramide.]
[M03BX01, baclofen, The risk or severity of sedation can be increased when Metoclopramide is combined with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of sedation can be increased when Metoclopramide is combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Metoclopramide can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Metoclopramide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Metoclopramide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Metoclopramide can be decreased when it is combined with Enzalutamide.]
[L04AA31, teriflunomide, The serum concentration of Metoclopramide can be decreased when it is combined with Teriflunomide.]
[H02AA01, aldosterone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Aldosterone.]
[N05CA04, barbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Barbital.]
[D02BA02, octinoxate, Metoclopramide may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Metoclopramide can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Metoclopramide.]
[S01GA07, brimonidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Brimonidine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Metoclopramide.]
[A03FA09, mosapride, The risk or severity of sedation can be increased when Metoclopramide is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of sedation can be increased when Metoclopramide is combined with Donepezil.]
[N03AX22, perampanel, The risk or severity of sedation can be increased when Metoclopramide is combined with Perampanel.]
[N02CC03, zolmitriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Zolmitriptan.]
[R06AC06, thonzylamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Thonzylamine.]
[G04BD10, darifenacin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Metoclopramide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of sedation can be increased when Metoclopramide is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Metoclopramide.]
[V08CA11, gadofosveset, Metoclopramide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Metoclopramide.]
[A16AX08, teduglutide, Metoclopramide may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Metoclopramide.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Metoclopramide can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of sedation can be increased when Metoclopramide is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Metoclopramide can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The metabolism of Metoclopramide can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Metoclopramide can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Metoclopramide can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Metoclopramide.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Metoclopramide.]
[R02AD01, benzocaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Benzocaine.]
[L03AA12, ancestim, Metoclopramide may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Metoclopramide can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Metoclopramide can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Metoclopramide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01EE01, trametinib, Metoclopramide may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of sedation can be increased when Metoclopramide is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Metoclopramide.]
[V09AX05, florbetapir F-18, Metoclopramide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bepridil.]
[A10BJ03, lixisenatide, Metoclopramide may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Metoclopramide may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Metoclopramide.]
[N06AX26, vortioxetine, The risk or severity of sedation can be increased when Metoclopramide is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of sedation can be increased when Metoclopramide is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Metoclopramide can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Metoclopramide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of sedation can be increased when Metoclopramide is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Metoclopramide may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, Metoclopramide may increase the bradycardic activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of sedation can be increased when Metoclopramide is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Metoclopramide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Metoclopramide can be increased when combined with Apremilast.]
[L02BG02, formestane, Metoclopramide may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, Metoclopramide may increase the bradycardic activities of Betaxolol.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Metoclopramide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ceritinib.]
[A03BA03, hyoscyamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Metoclopramide.]
[L01XH04, belinostat, The metabolism of Metoclopramide can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of sedation can be increased when Metoclopramide is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CM19, suvorexant, The risk or severity of sedation can be increased when Metoclopramide is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Metoclopramide can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Metoclopramide can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.]
[V04CX03, methacholine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Methacholine.]
[A06AH03, naloxegol, The therapeutic efficacy of Naloxegol can be increased when used in combination with Metoclopramide.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Metoclopramide.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Metoclopramide.]
[S03AA06, gentamicin, Metoclopramide may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Metoclopramide.]
[B01AF03, edoxaban, Metoclopramide may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Metoclopramide may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Metoclopramide can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Metoclopramide can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Metoclopramide.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03AA09, difemerine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Metoclopramide can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Eluxadoline can be increased when used in combination with Metoclopramide.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Metoclopramide can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of sedation can be increased when Metoclopramide is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Metoclopramide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Metoclopramide can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Metoclopramide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Metoclopramide.]
[J02AC05, isavuconazole, The metabolism of Metoclopramide can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Metoclopramide can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metoclopramide.]
[L01XG03, ixazomib, Metoclopramide may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Metoclopramide.]
[M04AB05, lesinurad, Metoclopramide may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of sedation can be increased when Metoclopramide is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Metoclopramide can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of sedation can be increased when Metoclopramide is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Metoclopramide may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of sedation can be increased when Metoclopramide is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of sedation can be increased when Metoclopramide is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of sedation can be increased when Metoclopramide is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Metoclopramide can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Bupivacaine.]
[C07AA19, bupranolol, Metoclopramide may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of sedation can be increased when Metoclopramide is combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N02AF01, butorphanol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Metoclopramide.]
[S01GX07, azelastine, The risk or severity of sedation can be increased when Metoclopramide is combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Metoclopramide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Metoclopramide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R03CC12, bambuterol, Metoclopramide may increase the neuromuscular blocking activities of Bambuterol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Metoclopramide.]
[A06AH05, naldemedine, Metoclopramide may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of sedation can be increased when Metoclopramide is combined with Pregabalin.]
[N03AX30, beclamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Metoclopramide can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxybuprocaine.]
[R05DB01, benzonatate, Metoclopramide may increase the neuromuscular blocking activities of Benzonatate.]
[P01CA02, benznidazole, Metoclopramide may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Metoclopramide.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Metoclopramide can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Metoclopramide.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Metoclopramide.]
[L04AB02, infliximab, The metabolism of Metoclopramide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Metoclopramide can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Metoclopramide.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Metoclopramide.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Bethanechol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetylcholine.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Metoclopramide.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vorinostat.]
[C07AB07, bisoprolol, Metoclopramide may increase the bradycardic activities of Bisoprolol.]
[J05AG03, efavirenz, The risk or severity of sedation can be increased when Metoclopramide is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C07AA17, bopindolol, Metoclopramide may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Metoclopramide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Budesonide.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Metoclopramide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CA03, butobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Metoclopramide.]
[N06AA15, butriptyline, The risk or severity of sedation can be increased when Metoclopramide is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be decreased when it is combined with Metoclopramide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of sedation can be increased when Metoclopramide is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Captopril is combined with Metoclopramide.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Metoclopramide can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of sedation can be increased when Metoclopramide is combined with Carbamazepine.]
[A03AA03, camylofine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Camylofin.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Metoclopramide.]
[R06AA08, carbinoxamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Metoclopramide may increase the bradycardic activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of sedation can be increased when Metoclopramide is combined with Cannabidiol.]
[L04AA37, baricitinib, Metoclopramide may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Metoclopramide.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Metoclopramide.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01GB14, plazomicin, Metoclopramide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Metoclopramide may increase the bradycardic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Metoclopramide.]
[L01XX62, ivosidenib, The metabolism of Metoclopramide can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Metoclopramide.]
[A16AX14, migalastat, Metoclopramide may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of sedation can be increased when Metoclopramide is combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Metoclopramide.]
[S01GX12, cetirizine, The risk or severity of sedation can be increased when Metoclopramide is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of sedation can be increased when Metoclopramide is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Metoclopramide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Metoclopramide.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of sedation can be increased when Metoclopramide is combined with Carisoprodol.]
[R03BB08, revefenacin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Revefenacin.]
[L04AA39, emapalumab, The metabolism of Metoclopramide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Metoclopramide can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amifampridine.]
[A06AX05, prucalopride, Metoclopramide may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Metoclopramide.]
[A03FA08, cinitapride, The risk or severity of sedation can be increased when Metoclopramide is combined with Cinitapride.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Metoclopramide can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of sedation can be increased when Metoclopramide is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of sedation can be increased when Metoclopramide is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of sedation can be increased when Metoclopramide is combined with Clobazam.]
[H02AB14, cloprednol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Cloxazolam.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Ubidecarenone.]
[L04AB01, etanercept, The metabolism of Metoclopramide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of sedation can be increased when Metoclopramide is combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Metoclopramide can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Metoclopramide can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Metoclopramide.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Metoclopramide.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of sedation can be increased when Metoclopramide is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Metoclopramide.]
[S01EX02, dapiprazole, The risk or severity of sedation can be increased when Metoclopramide is combined with Dapiprazole.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[H02AB13, deflazacort, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Deflazacort.]
[N02CC08, lasmiditan, The risk or severity of sedation can be increased when Metoclopramide is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Metoclopramide can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Metoclopramide can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Metoclopramide may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Metoclopramide.]
[S01XA12, dexpanthenol, Metoclopramide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The risk or severity of sedation can be increased when Metoclopramide is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Metoclopramide can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Metoclopramide can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Metoclopramide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Metoclopramide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of sedation can be increased when Metoclopramide is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Metoclopramide.]
[R02AA03, dichlorobenzyl alcohol, Metoclopramide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Metoclopramide may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of sedation can be increased when Metoclopramide is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Metoclopramide can be decreased when combined with Rofecoxib.]
[C08CA16, clevidipine, Metoclopramide may increase the neuromuscular blocking activities of Clevidipine.]
[C01BD07, dronedarone, The metabolism of Metoclopramide can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Valpromide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of sedation can be increased when Metoclopramide is combined with Chlordiazepoxide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Metoclopramide.]
[A03AA08, dihexyverine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Metoclopramide can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Metoclopramide.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Metoclopramide.]
[D07XB03, fluprednidene, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[V08CA05, mangafodipir, Metoclopramide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of sedation can be increased when Metoclopramide is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of sedation can be increased when Metoclopramide is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of sedation can be increased when Metoclopramide is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Metoclopramide can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Metoclopramide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Metoclopramide can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[D01AE07, chlorphenesin, The risk or severity of sedation can be increased when Metoclopramide is combined with Chlorphenesin.]
[R06AB04, chlorpheniramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of sedation can be increased when Metoclopramide is combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Metoclopramide can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of sedation can be increased when Metoclopramide is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N02BA03, choline salicylate, Metoclopramide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of sedation can be increased when Metoclopramide is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethyl loflazepate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Etofibrate.]
[B06AC06, berotralstat, The metabolism of Metoclopramide can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Metoclopramide can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Metoclopramide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Metoclopramide can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Metoclopramide can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of sedation can be increased when Metoclopramide is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of sedation can be increased when Metoclopramide is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Metoclopramide.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Metoclopramide.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Flumequine.]
[R03BA03, flunisolide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flunisolide.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocinolone acetonide.]
[N02BG07, flupirtine, Metoclopramide may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Metoclopramide.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Metoclopramide.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Metoclopramide.]
[N01AB05, trichloroethylene, The risk or severity of sedation can be increased when Metoclopramide is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Metoclopramide can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.]
[A02BA01, cimetidine, The metabolism of Metoclopramide can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of sedation can be increased when Metoclopramide is combined with Gabapentin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Metoclopramide.]
[J01MB06, cinoxacin, The metabolism of Metoclopramide can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Metoclopramide can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Metoclopramide can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Metoclopramide may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of sedation can be increased when Metoclopramide is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Metoclopramide can be increased when combined with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Metoclopramide can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Metoclopramide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Metoclopramide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Metoclopramide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of sedation can be increased when Metoclopramide is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Metoclopramide can be decreased when combined with Mefenamic acid.]
[N06AX25, St. John's wort extract, The risk or severity of sedation can be increased when Metoclopramide is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Metoclopramide can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Metoclopramide.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Metoclopramide.]
[N01BB10, levobupivacaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Metoclopramide can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.]
[J01GB12, arbekacin, Metoclopramide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Metoclopramide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Metoclopramide.]
[L04AC21, bimekizumab, The metabolism of Metoclopramide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R05DA04, codeine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of sedation can be increased when Metoclopramide is combined with Hexafluronium.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Colchicine.]
[A03AB10, hexocyclium, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hexocyclium.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Homatropine methylbromide.]
[S01FA05, homatropine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Homatropine.]
[J01XB01, colistin, Metoclopramide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L04AA13, leflunomide, The serum concentration of Metoclopramide can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of sedation can be increased when Metoclopramide is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of sedation can be increased when Metoclopramide is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Metoclopramide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Metoclopramide.]
[J01FA15, telithromycin, The metabolism of Metoclopramide can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of sedation can be increased when Metoclopramide is combined with Desloratadine.]
[J05AB14, valganciclovir, Metoclopramide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Metoclopramide may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Metoclopramide may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Metoclopramide may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Metoclopramide may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Metoclopramide may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Metoclopramide can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Metoclopramide can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Metoclopramide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lacidipine.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Metoclopramide.]
[N03AX09, lamotrigine, The risk or severity of sedation can be increased when Metoclopramide is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of sedation can be increased when Metoclopramide is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Metoclopramide.]
[S01BA03, cortisone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Metoclopramide can be decreased when combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Metoclopramide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Metoclopramide can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Medifoxamine.]
[C07AA14, mepindolol, Metoclopramide may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Metoclopramide.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Adenosine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Metoclopramide.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of sedation can be increased when Metoclopramide is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01FA04, cyclopentolate, Cyclopentolate may increase the anticholinergic activities of Metoclopramide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Metoclopramide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Metoclopramide.]
[S01XA18, cyclosporine, Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.]
[N06BA07, modafinil, The metabolism of Metoclopramide can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of sedation can be increased when Metoclopramide is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Metoclopramide.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Rosuvastatin is combined with Metoclopramide.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Metoclopramide can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Metoclopramide.]
[J05AF10, entecavir, The metabolism of Metoclopramide can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Metoclopramide.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Metoclopramide.]
[L01AX04, dacarbazine, The metabolism of Metoclopramide can be decreased when combined with Dacarbazine.]
[G03XA01, danazol, The metabolism of Metoclopramide can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of sedation can be increased when Metoclopramide is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Metoclopramide.]
[N06BX04, deanol, The risk or severity of sedation can be increased when Metoclopramide is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Metoclopramide.]
[A04AD11, nabilone, The risk or severity of sedation can be increased when Metoclopramide is combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Metoclopramide can be decreased when combined with Nabumetone.]
[N07BB05, nalmefene, Metoclopramide may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Nordazepam.]
[C07AB12, nebivolol, Metoclopramide may increase the bradycardic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of sedation can be increased when Metoclopramide is combined with Niaprazine.]
[C01DX16, nicorandil, Metoclopramide may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of sedation can be increased when Metoclopramide is combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Metoclopramide.]
[M03AC11, cisatracurium, The risk or severity of sedation can be increased when Metoclopramide is combined with Cisatracurium.]
[R05DA06, normethadone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of sedation can be increased when Metoclopramide is combined with Escitalopram.]
[G04BD08, solifenacin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[D07XC02, desoximetasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Desoximetasone.]
[V04CH02, indigo carmine, Metoclopramide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Desoxycortone.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Metoclopramide.]
[G04BD04, oxybutynin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Metoclopramide.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Metoclopramide can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Metoclopramide.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Metoclopramide.]
[R05DA09, dextromethorphan, The risk or severity of sedation can be increased when Metoclopramide is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of sedation can be increased when Metoclopramide is combined with Paramethadione.]
[N02AC01, dextromoramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dextromoramide.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Metoclopramide.]
[N06AB05, paroxetine, The risk or severity of sedation can be increased when Metoclopramide is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Metoclopramide can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Metoclopramide.]
[P03AC04, permethrin, Metoclopramide may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of sedation can be increased when Metoclopramide is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of sedation can be increased when Metoclopramide is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of sedation can be increased when Metoclopramide is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Cinchocaine.]
[R05DA08, pholcodine, Metoclopramide may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Metoclopramide can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Metoclopramide.]
[A03AA07, dicyclomine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipamperone.]
[A03AB14, pipenzolate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Metoclopramide.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of sedation can be increased when Metoclopramide is combined with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Metoclopramide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Digitoxin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be decreased when it is combined with Metoclopramide.]
[C02DB01, dihydralazine, The metabolism of Metoclopramide can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Metoclopramide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Metoclopramide.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Metoclopramide.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of sedation can be increased when Metoclopramide is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Metoclopramide can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of sedation can be increased when Metoclopramide is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Metoclopramide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of sedation can be increased when Metoclopramide is combined with Pridinol.]
[R06AB03, dimethindene, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Metoclopramide can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of sedation can be increased when Metoclopramide is combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Metoclopramide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Metoclopramide.]
[R06AA02, diphenhydramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of sedation can be increased when Metoclopramide is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Quazepam.]
[B01AC07, dipyridamole, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of sedation can be increased when Metoclopramide is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of sedation can be increased when Metoclopramide is combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.]
[S01AX06, resorcinol, Metoclopramide may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Metoclopramide.]
[S02AA12, rifamycin SV, The metabolism of Metoclopramide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Metoclopramide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of sedation can be increased when Metoclopramide is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of sedation can be increased when Metoclopramide is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Metoclopramide.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Metoclopramide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Metoclopramide.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Metoclopramide can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Metoclopramide.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Metoclopramide.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of sedation can be increased when Metoclopramide is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of sedation can be increased when Metoclopramide is combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Metoclopramide can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Doxylamine.]
[N06AB06, sertraline, The risk or severity of sedation can be increased when Metoclopramide is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of sedation can be increased when Metoclopramide is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sibutramine.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Metoclopramide.]
[A12CA02, sodium sulfate, Metoclopramide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Sumatriptan.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C07AB13, talinolol, Metoclopramide may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Metoclopramide can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Terodiline.]
[C07AA16, tertatolol, Metoclopramide may increase the bradycardic activities of Tertatolol.]
[M03BX07, tetrazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of sedation can be increased when Metoclopramide is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of sedation can be increased when Metoclopramide is combined with Emepronium.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of sedation can be increased when Metoclopramide is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Metoclopramide.]
[N05BA23, tofisopam, The risk or severity of sedation can be increased when Metoclopramide is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Toloxatone is combined with Metoclopramide.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Metoclopramide.]
[N03AX11, topiramate, The risk or severity of sedation can be increased when Metoclopramide is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of sedation can be increased when Metoclopramide is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of sedation can be increased when Metoclopramide is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of sedation can be increased when Metoclopramide is combined with Triclofos.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tridihexethyl.]
[H02CA01, trilostane, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trilostane.]
[R06AA10, trimethobenzamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Trimethobenzamide.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triptorelin.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Metoclopramide.]
[N01AB04, enflurane, The risk or severity of sedation can be increased when Metoclopramide is combined with Enflurane.]
[C02CA06, urapidil, The risk or severity of sedation can be increased when Metoclopramide is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Metoclopramide can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Metoclopramide can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Metoclopramide may increase the neuromuscular blocking activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of sedation can be increased when Metoclopramide is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Metoclopramide can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The risk or severity of sedation can be increased when Metoclopramide is combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Metoclopramide.]
[N05CF01, zopiclone, The risk or severity of sedation can be increased when Metoclopramide is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of sedation can be increased when Metoclopramide is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Metoclopramide.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of sedation can be increased when Metoclopramide is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of sedation can be increased when Metoclopramide is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of sedation can be increased when Metoclopramide is combined with Valproic acid.]
[L03AX05, pidotimod, Metoclopramide may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Metoclopramide can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Metoclopramide can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Metoclopramide can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Metoclopramide can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R03BA05, fluticasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fluvastatin is combined with Metoclopramide.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethchlorvynol.]
[L02AA03, ethinyl estradiol, The metabolism of Metoclopramide can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Metoclopramide.]
[N03AD01, ethosuximide, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of sedation can be increased when Metoclopramide is combined with Etomidate.]
[L01CB01, etoposide, The metabolism of Metoclopramide can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Metoclopramide.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Metoclopramide.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Metoclopramide.]
[R06AX12, terfenadine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of sedation can be increased when Metoclopramide is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Metoclopramide can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Metoclopramide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Metoclopramide.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Metoclopramide.]
[M01CB01, gold sodium thiomalate, Metoclopramide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Metoclopramide may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Metoclopramide can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Metoclopramide.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R03CC04, fenoterol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fenoterol.]
[N02AB03, fentanyl, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Metoclopramide.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Metoclopramide.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Metoclopramide.]
[G04BD02, flavoxate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Metoclopramide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Metoclopramide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fludrocortisone.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[D07XB01, flumethasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flumethasone.]
[N07CA03, flunarizine, The risk or severity of sedation can be increased when Metoclopramide is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of sedation can be increased when Metoclopramide is combined with Melitracen.]
[H02AB03, fluocortolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of sedation can be increased when Metoclopramide is combined with Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01CB05, fluorometholone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluorometholone.]
[L01BC02, fluorouracil, The metabolism of Metoclopramide can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of sedation can be increased when Metoclopramide is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of extrapyramidal symptoms can be increased when Flupentixol is combined with Metoclopramide.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Metoclopramide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S02AA17, fosfomycin, Metoclopramide can cause a decrease in the absorption of Fosfomycin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Metoclopramide.]
[M03AA01, alcuronium, The risk or severity of sedation can be increased when Metoclopramide is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Metoclopramide.]
[J05AE10, darunavir, The metabolism of Metoclopramide can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide.]
[N05CF04, eszopiclone, The risk or severity of sedation can be increased when Metoclopramide is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Metoclopramide.]
[M03AC02, gallamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Metoclopramide.]
[N03AA04, barbexaclone, The risk or severity of sedation can be increased when Metoclopramide is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of sedation can be increased when Metoclopramide is combined with Bifemelane.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of sedation can be increased when Metoclopramide is combined with Cabergoline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Metoclopramide.]
[N03AD03, methsuximide, The risk or severity of sedation can be increased when Metoclopramide is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lapatinib.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of sedation can be increased when Metoclopramide is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Metoclopramide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Metoclopramide.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Metoclopramide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Metoclopramide.]
[C07AB09, esmolol, Metoclopramide may increase the bradycardic activities of Esmolol.]
[M01CB04, aurothioglucose, Metoclopramide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Metoclopramide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Metoclopramide can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of sedation can be increased when Metoclopramide is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.]
[N06BX13, idebenone, Metoclopramide may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Metoclopramide.]
[N02CX03, iprazochrome, The risk or severity of sedation can be increased when Metoclopramide is combined with Iprazochrome.]
[L01CE02, irinotecan, Metoclopramide may increase the neuromuscular blocking activities of Irinotecan.]
[N05CA21, allobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Metoclopramide.]
[G03DC01, allylestrenol, Metoclopramide may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Metoclopramide.]
[C08CA10, nilvadipine, The metabolism of Metoclopramide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxatomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C02DB02, hydralazine, Metoclopramide may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Metoclopramide.]
[R05DA03, hydrocodone, The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Metoclopramide.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Metoclopramide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[G04BD06, propiverine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Prothipendyl.]
[B05AA07, hetastarch, Metoclopramide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Hydroxyurea is combined with Metoclopramide.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Hydroxyzine.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Metoclopramide.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[B05XA08, sodium acetate, Metoclopramide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Metoclopramide.]
[L01AA06, ifosfamide, The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Metoclopramide.]
[H01AC02, somatrem, The metabolism of Metoclopramide can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Paclitaxel is combined with Metoclopramide.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Terlipressin.]
[R01AD07, tixocortol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of sedation can be increased when Metoclopramide is combined with Tizanidine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Metoclopramide.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A11HA07, inositol, Metoclopramide may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.]
[A03AA30, piperidolate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Piperidolate.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Varenicline.]
[N01BB08, articaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Articaine.]
[A10BH01, sitagliptin, Metoclopramide may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of sedation can be increased when Metoclopramide is combined with Ramelteon.]
[R06AE01, buclizine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Buclizine.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Metoclopramide.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of sedation can be increased when Metoclopramide is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The metabolism of Metoclopramide can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Metoclopramide.]
[N06AA13, iprindole, The risk or severity of sedation can be increased when Metoclopramide is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Metoclopramide.]
[J05AB13, penciclovir, The metabolism of Metoclopramide can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.]
[P01AX06, atovaquone, Metoclopramide can cause a decrease in the absorption of Atovaquone resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB06, isoflurane, The risk or severity of sedation can be increased when Metoclopramide is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of sedation can be increased when Metoclopramide is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Metoclopramide can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Metoclopramide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Isosorbide mononitrate is combined with Metoclopramide.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Isosorbide dinitrate is combined with Metoclopramide.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Metoclopramide.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Metoclopramide.]
[N06AX18, reboxetine, The risk or severity of sedation can be increased when Metoclopramide is combined with Reboxetine.]
[S01AA24, kanamycin, Metoclopramide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Metoclopramide.]
[L04AC07, tocilizumab, The metabolism of Metoclopramide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of sedation can be increased when Metoclopramide is combined with Ketanserin.]
[B01AC22, prasugrel, Metoclopramide may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Metoclopramide can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Metoclopramide can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[V03AC03, deferasirox, The serum concentration of Metoclopramide can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Metoclopramide can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mizolastine.]
[N04BC09, rotigotine, The risk or severity of sedation can be increased when Metoclopramide is combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C07AG01, labetalol, Metoclopramide may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of sedation can be increased when Metoclopramide is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lidoflazine.]
[S01AA21, amikacin, Metoclopramide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Metoclopramide can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of sedation can be increased when Metoclopramide is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of sedation can be increased when Metoclopramide is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Metoclopramide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.]
[L01EG01, temsirolimus, The metabolism of Metoclopramide can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Metoclopramide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Metoclopramide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of sedation can be increased when Metoclopramide is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Metoclopramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Metoclopramide can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of sedation can be increased when Metoclopramide is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of sedation can be increased when Metoclopramide is combined with Mazindol.]
[C02BB01, mecamylamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mecamylamine.]
[R06AE05, meclizine, The risk or severity of sedation can be increased when Metoclopramide is combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Medazepam.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be decreased when it is combined with Metoclopramide.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Metoclopramide.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of sedation can be increased when Metoclopramide is combined with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Metoclopramide.]
[N02AB02, meperidine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Meperidine.]
[M03BX06, mephenesin, The risk or severity of sedation can be increased when Metoclopramide is combined with Mephenesin.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of sedation can be increased when Metoclopramide is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of sedation can be increased when Metoclopramide is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of sedation can be increased when Metoclopramide is combined with Meprobamate.]
[N02AX05, meptazinol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Metoclopramide may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Dolasetron.]
[N07BC02, methadone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methadone.]
[N06BA03, methamphetamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Metamfetamine.]
[A03AB07, methantheline, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The risk or severity of sedation can be increased when Metoclopramide is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of sedation can be increased when Metoclopramide is combined with Methaqualone.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Metoclopramide.]
[N03AA30, metharbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Metharbital.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of sedation can be increased when Metoclopramide is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Metoclopramide can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Metoclopramide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of sedation can be increased when Metoclopramide is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of sedation can be increased when Metoclopramide is combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of sedation can be increased when Metoclopramide is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Metoclopramide.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Metoclopramide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of sedation can be increased when Metoclopramide is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Metoclopramide.]
[V04CG05, methylene blue, Metoclopramide may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Metoclopramide can be decreased when combined with Aminophylline.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone aceponate.]
[N03AF03, rufinamide, The risk or severity of sedation can be increased when Metoclopramide is combined with Rufinamide.]
[G03EK01, methyltestosterone, Metoclopramide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of sedation can be increased when Metoclopramide is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of sedation can be increased when Metoclopramide is combined with Methysergide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pipemidic acid.]
[N07XX04, sodium oxybate, The risk or severity of sedation can be increased when Metoclopramide is combined with Sodium oxybate.]
[C01DA05, pentaerythritol tetranitrate, Metoclopramide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluticasone furoate.]
[J01MB02, nalidixic acid, The metabolism of Metoclopramide can be decreased when combined with Nalidixic acid.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Metoclopramide can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Metoclopramide.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Metoclopramide can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of sedation can be increased when Metoclopramide is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Metoclopramide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Metoclopramide.]
[N05CD08, midazolam, The risk or severity of sedation can be increased when Metoclopramide is combined with Midazolam.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Metoclopramide.]
[L01XX23, mitotane, The metabolism of Metoclopramide can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Metoclopramide.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Metoclopramide can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Metoclopramide.]
[N02AA01, morphine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Metoclopramide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Metoclopramide.]
[G04BA01, ammonium chloride, Metoclopramide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Metoclopramide.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of sedation can be increased when Metoclopramide is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Amobarbital.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Metoclopramide.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of sedation can be increased when Metoclopramide is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, Metoclopramide may increase the bradycardic activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.]
[J01CF06, nafcillin, The metabolism of Metoclopramide can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of sedation can be increased when Metoclopramide is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Metoclopramide can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Naltrexone can be increased when used in combination with Metoclopramide.]
[L04AC03, anakinra, The metabolism of Metoclopramide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Metoclopramide.]
[M02AA12, naproxen, The metabolism of Metoclopramide can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of sedation can be increased when Metoclopramide is combined with Tolcapone.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Metoclopramide.]
[S03AA01, neomycin, Metoclopramide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Metoclopramide.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[L03AX16, plerixafor, Metoclopramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Metoclopramide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C01CE01, inamrinone, Metoclopramide may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Metoclopramide.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Metoclopramide.]
[C08CA04, nicardipine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Metoclopramide.]
[P02DA01, niclosamide, The metabolism of Metoclopramide can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Metoclopramide.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Nimodipine.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Metoclopramide.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Metoclopramide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Metoclopramide.]
[N05CF03, zaleplon, The risk or severity of sedation can be increased when Metoclopramide is combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Metoclopramide.]
[N01AX13, nitrous oxide, The risk or severity of sedation can be increased when Metoclopramide is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of sedation can be increased when Metoclopramide is combined with Nomifensine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Metoclopramide.]
[N06AA10, nortriptyline, The risk or severity of sedation can be increased when Metoclopramide is combined with Nortriptyline.]
[L03AB07, interferon beta-1a, The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1a.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Metoclopramide.]
[L04AC04, rilonacept, The metabolism of Metoclopramide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Metoclopramide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of sedation can be increased when Metoclopramide is combined with Opipramol.]
[N02AA02, opium, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Metoclopramide.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Metoclopramide can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.]
[J04AA01, aminosalicylic acid, The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Metoclopramide.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.]
[N02AX06, tapentadol, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of sedation can be increased when Metoclopramide is combined with Pancuronium.]
[J04AB30, capreomycin, Metoclopramide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Papaverine.]
[N05CC05, paraldehyde, The risk or severity of sedation can be increased when Metoclopramide is combined with Paraldehyde.]
[H02AB05, paramethasone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Metoclopramide.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Metoclopramide.]
[G04BD11, fesoterodine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of sedation can be increased when Metoclopramide is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Penicillamine is combined with Metoclopramide.]
[J01CE09, penicillin G procaine, Metoclopramide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Pentobarbital.]
[L01XX08, pentostatin, Metoclopramide may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Metoclopramide can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of sedation can be increased when Metoclopramide is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Metoclopramide can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Metoclopramide.]
[N02AD02, phenazocine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Metoclopramide.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pheniramine.]
[N03AA02, phenobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Phenobarbital.]
[N01AH04, phenoperidine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Metoclopramide.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01GA05, phenylephrine, The metabolism of Metoclopramide can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The risk or severity of sedation can be increased when Metoclopramide is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Metoclopramide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levofloxacin.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Metoclopramide can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pilocarpine.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of sedation can be increased when Metoclopramide is combined with Pindolol.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Metoclopramide.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Metoclopramide can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Metoclopramide.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine.]
[N06BX03, piracetam, Metoclopramide may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Metoclopramide.]
[A02BX03, pirenzepine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Metoclopramide.]
[N02AC03, pirinitramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of sedation can be increased when Metoclopramide is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Metoclopramide can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of sedation can be increased when Metoclopramide is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of sedation can be increased when Metoclopramide is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Metoclopramide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Metoclopramide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Metoclopramide may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Metoclopramide.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Metoclopramide.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Pitavastatin.]
[C07AB01, practolol, Metoclopramide may increase the bradycardic activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Prajmaline.]
[N05BA11, prazepam, The risk or severity of sedation can be increased when Metoclopramide is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Metoclopramide can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Metoclopramide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of sedation can be increased when Metoclopramide is combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Metoclopramide.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Metoclopramide.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Metoclopramide.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Metoclopramide.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Metoclopramide.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Metoclopramide can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of sedation can be increased when Metoclopramide is combined with Propanidid.]
[A03AB05, propantheline, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of sedation can be increased when Metoclopramide is combined with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of sedation can be increased when Metoclopramide is combined with Propofol.]
[N02AC04, propoxyphene, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Metoclopramide may increase the bradycardic activities of Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Metoclopramide.]
[N02CC04, rizatriptan, The risk or severity of sedation can be increased when Metoclopramide is combined with Rizatriptan.]
[B01AC09, epoprostenol, Metoclopramide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Metoclopramide.]
[N06AA11, protriptyline, The risk or severity of sedation can be increased when Metoclopramide is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Metoclopramide.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.]
[N07XX07, dalfampridine, Metoclopramide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Diphemanil.]
[A03AB09, isopropamide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Isopropamide.]
[S01FA03, methscopolamine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methscopolamine.]
[N05CA07, talbutal, The risk or severity of sedation can be increased when Metoclopramide is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of sedation can be increased when Metoclopramide is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of sedation can be increased when Metoclopramide is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Mepyramine.]
[C01BA01, quinidine, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Quinidine.]
[P01BC01, quinine, The risk or severity of sedation can be increased when Metoclopramide is combined with Quinine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Metoclopramide.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Metoclopramide can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of sedation can be increased when Metoclopramide is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Metoclopramide.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[S01FA02, scopolamine, The risk or severity of sedation can be increased when Metoclopramide is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of sedation can be increased when Metoclopramide is combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.]
[J01GB08, sisomicin, Metoclopramide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Metoclopramide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Metoclopramide may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Metoclopramide.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ipratropium.]
